A
AUPH icon

Abingworth’s Aurinia Pharmaceuticals AUPH Stock Holding History

Abingworth’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-400,434
Closed -$2.72M – 16
2018
Q4 		$2.72M Hold
400,434
– – 2.47% 9
2018
Q3 		$2.65M Hold
400,434
– – 1.58% 12
2018
Q2 		$2.25M Buy
400,434
+148,305
+59% +$827K 1.29% 13
2018
Q1 		$1.31M Hold
252,129
– – 0.81% 14
2017
Q4 		$1.14M Hold
252,129
– – 0.83% 16
2017
Q3 		$1.58M Hold
252,129
– – 1.09% 16
2017
Q2 		$1.54M Hold
252,129
– – 1.23% 13
2017
Q1 		$1.85M Buy
+252,129
New +$1.16M 1.38% 12
2016
Q4 		– Sell
-437,994
Closed -$1.38M – 19
2016
Q3 		$1.38M Sell
437,994
-74,042
-14% -$200K 1.32% 17
2016
Q2 		$1.39M Buy
512,036
+423,729
+480% +$1.16M 1.45% 16
2016
Q1 		$256K Buy
+88,307
New +$214K 0.24% 18

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Abingworth's AUPH Position: Q1 2019 in Review

Abingworth sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2019, closing a stake of 400,434 shares — an estimated $2.72M sold.

Abingworth first reported a position in AUPH in Q1 2016 and held it in 11 quarters. The position peaked at $2.72M in Q4 2018. 78 funds tracked by Wall St. Rank hold AUPH as of Q1 2019.

  • Abingworth reported no remaining Aurinia Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Abingworth sold 400,434 Aurinia Pharmaceuticals shares in Q1 2019, an estimated $2.72M.
  • Abingworth first reported a position in Aurinia Pharmaceuticals in Q1 2016 and held it in 11 quarters.
  • Abingworth's Aurinia Pharmaceuticals position peaked at $2.72M in Q4 2018.
  • 78 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2019.

Based on Abingworth's 13F filing for Q1 2019, filed 15 May 2019.